GSK Revises Licensing Deal for Scynexis Antifungal Agent
🌥️Trending News SCYNEXIS ($NASDAQ:SCYX) is a publicly traded company focused on the development of innovative therapeutics to address unmet medical [...]
SCYNEXIS: GSK Partnership, Revenue Potential and 2-Year Cash Runway Make Stock a ‘Buy’
🌥️Trending News SCYNEXIS ($NASDAQ:SCYX), a biotechnology company located in Durham, North Carolina, is focused on developing anti-infective treatments to address [...]
SCYNEXIS Reports Impressive Q3 Financials, Exceeds Expectations
Trending News ☀️ The company reported a GAAP EPS of -$0.30, exceeding analyst expectations of -$0.40. Moreover, revenue of $1.4M [...]
SCYNEXIS Misses Q3 EPS Estimate by $0. 12
Trending News 🌧️ Scynexis Intrinsic Stock Value – SCYNEXIS ($NASDAQ:SCYX) is a pharmaceutical company that focuses on the development of [...]
SCYNEXIS Announces New CFO Ivor Macleod
Trending News 🌥️ SCYNEXIS ($NASDAQ:SCYX), Inc. is a biopharmaceutical company based in Durham, North Carolina that is focused on the [...]
SCYNEXIS Announces Leadership Changes, Workforce Reduction
Trending News 🌥️ Scynexis Intrinsic Value – Scynexis ($NASDAQ:SCYX), Inc., a biotech company focused on fungal infections, fell in pre-market [...]
